Țară: Canada
Limbă: engleză
Sursă: Health Canada
PROPRANOLOL HYDROCHLORIDE
PFIZER CANADA ULC
C07AA05
PROPRANOLOL
120MG
CAPSULE (EXTENDED RELEASE)
PROPRANOLOL HYDROCHLORIDE 120MG
ORAL
100
Prescription
BETA-ADRENERGIC BLOCKING AGENTS
Active ingredient group (AIG) number: 0101831001; AHFS:
CANCELLED POST MARKET
2022-05-31
_INDERAL-LA (propranolol hydrochloride) Product Monograph_ _ _ _Page 1 of 29_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR INDERAL ® -LA Propranolol Hydrochloride Extended-Release Capsules Extended-Release Capsules, 60 mg, 80 mg, 120 mg and 160 mg, Oral USP Beta-Adrenergic Receptor Blocking Agent Pfizer Canada ULC Kirkland, Quebec H9J 2M5 Date of Initial Authorization: SEP 21, 2010 Date of Revision: June 16, 2021 Submission Control Number: 248972 ® Trademark AstraZeneca UK Limited _ _ _INDERAL-LA (propranolol hydrochloride) Product Monograph _ _Page 2 of 29_ RECENT MAJOR LABEL CHANGES TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics .......................................................................................................... 4 1.2 Geriatrics........................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION................................................................................. 5 4.1 Dosing Considerations ....................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment..................................................... 5 4.4 Administration................................................................................................... 6 4.5 Missed Dose ..... Citiți documentul complet